Search
alectinib (Alecensa)
Indications:
- ALK*+ non-small cell lung cancer (NSCLC) in patients who fail crizotinib [1]
- alectinib superior to crizotinib with lower toxicity in untreated ALK*+ NSCLC [2]
- may benefit patients with brain metastases [1]
* ALK = anaplastic lymphoma kinase
Contraindications:
- pregnancy, lactation
Dosage:
Capsule: 150 mg
Adverse effects:
- most cammon
- fatigue (41%), constipation (34%), edema (30%),
- myalgia (29%) with increased serum creatine kinase
- other
- hepatoxicity, increased serum transaminases
- interstitial lung disease
- bradycardia
- photosensitivity
Mechanism of action:
- inhibits anaplastic lymphoma kinase
General
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM correlations
References
- FDA News Release. December 11, 2015
FDA approves new oral therapy to treat ALK-positive lung cancer.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476926.htm
- Peters S, Camidge DR, Shaw AT et al
Alectinib versus Crizotinib in Untreated ALK-Positive Non-
Small-Cell Lung Cancer.
N Engl J Med 2017; 377:829-838. August 31, 2017
PMID: 28586279 Free full text
http://www.nejm.org/doi/full/10.1056/NEJMoa1704795
- Prescribing Information:
https://www.alecensa.com/hcp.html